tiprankstipranks
Advertisement

PRFZ - ETF AI Analysis

Compare

Top Page

PRFZ

Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ)

Rating:65Neutral
Price Target:
PRFZ, the Invesco FTSE RAFI US 1500 Small-Mid ETF, has a solid overall rating supported by strong holdings like Onto Innovation and ATI, which benefit from healthy financial performance, positive earnings calls, and bullish technical trends. Additional contributors such as TTM Technologies, Iridium Communications, Viavi Solutions, and Carpenter Technology add to the fund’s quality through solid fundamentals and constructive corporate events, though often with some valuation concerns. The main risks come from weaker names like Maxlinear, Roivant Sciences, and Revolution Medicines, where financial difficulties, negative earnings, and bearish or mixed technical trends highlight the fund’s exposure to companies with operational and profitability challenges.
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the last few months, indicating solid recent momentum.
Broad Sector Diversification
Holdings are spread across many sectors like technology, health care, industrials, and financials, which helps reduce the impact of weakness in any single industry.
Growing, Well-Established Fund
With several billion dollars in assets, the ETF is a sizable, established product that appears to attract and retain investor capital.
Negative Factors
High U.S. Concentration
Almost all of the ETF’s holdings are in U.S. companies, offering very limited international diversification.
Moderate Expense Ratio
The fund’s fees are not extremely high but are also not among the lowest, which slightly reduces the net return to investors over time.
Small-Mid Cap Volatility Risk
Because the ETF focuses on smaller and mid-sized companies, its share price can be more sensitive to market swings than large-cap funds.

PRFZ vs. SPDR S&P 500 ETF (SPY)

PRFZ Summary

PRFZ is the Invesco FTSE RAFI US 1500 Small-Mid ETF, which follows the FTSE RAFI US 1500 Small-Mid Index. It focuses on smaller and mid-sized U.S. companies across many sectors, including technology, health care, and industrials. The fund uses a rules-based approach that looks at things like company profits and dividends instead of just size. It holds lesser-known but growing firms such as Iridium Communications and Onto Innovation. Investors might consider PRFZ for long-term growth and diversification beyond big-name stocks. A key risk is that smaller companies can be more volatile, so the ETF’s price can move up and down sharply with the market.
How much will it cost me?The expense ratio for the Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) is 0.34%, which means you’ll pay $3.40 per year for every $1,000 invested. This is slightly higher than average for ETFs because it uses an actively managed strategy based on fundamental factors rather than passive market-cap weighting.
What would affect this ETF?The PRFZ ETF, which focuses on small to mid-cap U.S. companies, could benefit from economic growth and innovation in sectors like technology and healthcare, which are heavily weighted in its portfolio. However, it may face challenges from rising interest rates or economic slowdowns, which can disproportionately impact smaller companies and cyclical sectors like consumer discretionary and industrials. Regulatory changes or shifts in market sentiment could also affect the performance of its top holdings and sector exposure.

PRFZ Top 10 Holdings

PRFZ is leaning on a mix of rising industrial and health-care names, with ATI and Carpenter Technology helping power returns as demand in aerospace and specialty metals stays strong. Biotech players like Roivant Sciences and Revolution Medicines are more of a wild card—showing upbeat momentum but still weighed down by losses. On the tech side, Maxlinear and Viavi have been climbing over the year, even if recent trading has been choppy, while Onto Innovation has lost a bit of steam lately. Overall, it’s a U.S.-focused, small‑mid cap fund with notable tilts toward technology, health care, and industrials.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Par Pacific Holdings0.43%$12.12M$4.31B171.44%
67
Neutral
ATI0.42%$11.94M$25.58B155.31%
78
Outperform
Roivant Sciences0.40%$11.18M$24.50B189.49%
58
Neutral
Iridium Communications0.39%$10.87M$5.02B95.94%
71
Outperform
Revolution Medicines0.39%$10.83M$39.87B390.72%
52
Neutral
TTM Technologies0.36%$10.12M$11.99B170.38%
77
Outperform
Enova International0.35%$9.90M$6.33B152.02%
71
Outperform
Carpenter Technology0.34%$9.68M$25.82B114.81%
75
Outperform
Onto Innovation0.34%$9.65M$12.86B176.22%
82
Outperform
Maxlinear0.34%$9.63M$6.06B340.06%
60
Neutral

PRFZ Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
53.60
Positive
100DMA
51.14
Positive
200DMA
48.92
Positive
Market Momentum
MACD
0.37
Negative
RSI
58.42
Neutral
STOCH
82.75
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PRFZ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 54.29, equal to the 50-day MA of 53.60, and equal to the 200-day MA of 48.92, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 58.42 is Neutral, neither overbought nor oversold. The STOCH value of 82.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRFZ.

PRFZ Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$2.87B0.34%
65
Neutral
$3.16B0.51%
65
Neutral
$2.85B0.24%
67
Neutral
$2.79B0.55%
68
Neutral
$2.51B0.15%
70
Outperform
$1.77B0.29%
67
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRFZ
Invesco FTSE RAFI US 1500 Small-Mid ETF
55.20
13.91
33.69%
CGMM
Capital Group U.S. Small and Mid Cap ETF
JMEE
JPMorgan Market Expansion Enhanced Equity ETF
TMSL
T. Rowe Price Small-Mid Cap ETF
FSMD
Fidelity Small-Mid Multifactor ETF
USVM
VictoryShares USAA MSCI USA Small Cap Value Momentum ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement